These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 21850283)

  • 41. Similar relationship between the time course of bone mineral density improvement and vertebral fracture risk reduction with denosumab treatment in postmenopausal osteoporosis and prostate cancer patients on androgen deprivation therapy.
    Pérez Ruixo JJ; Zheng J; Mandema JW
    J Clin Pharmacol; 2014 May; 54(5):503-12. PubMed ID: 24214315
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Denosumab: anti-RANKL antibody.
    Miller PD
    Curr Osteoporos Rep; 2009 Mar; 7(1):18-22. PubMed ID: 19239825
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Denosumab: recent update in postmenopausal osteoporosis.
    Silva I; Branco JC
    Acta Reumatol Port; 2012; 37(4):302-13. PubMed ID: 24126422
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Austrian guidance for the pharmacologic treatment of osteoporosis in postmenopausal women: Addendum 2010].
    Dimai HP; Pietschmann P; Resch H; Preisinger E; Fahrleitner-Pammer A; Dobnig H; Klaushofer K;
    Wien Med Wochenschr; 2010 Dec; 160(21-22):586-9. PubMed ID: 21170699
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Therapeutic agents for disorders of bone and calcium metabolism--Denosumab, a fully human monoclocal antibody-targeting RANKL as a therapy for cancer-induced bone diseases].
    Mera K; Ito K
    Clin Calcium; 2007 Jan; 17(1):37-46. PubMed ID: 17211092
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Updates of denosumab, anti-RANKL antibody for osteoporosis].
    Tokuyama N; Tanaka S
    Clin Calcium; 2014 Jan; 24(1):85-91. PubMed ID: 24369284
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Denosumab and bisphosphonates: different mechanisms of action and effects.
    Baron R; Ferrari S; Russell RG
    Bone; 2011 Apr; 48(4):677-92. PubMed ID: 21145999
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
    Bone HG; Bolognese MA; Yuen CK; Kendler DL; Miller PD; Yang YC; Grazette L; San Martin J; Gallagher JC
    J Clin Endocrinol Metab; 2011 Apr; 96(4):972-80. PubMed ID: 21289258
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial.
    Brown JP; Prince RL; Deal C; Recker RR; Kiel DP; de Gregorio LH; Hadji P; Hofbauer LC; Alvaro-Gracia JM; Wang H; Austin M; Wagman RB; Newmark R; Libanati C; San Martin J; Bone HG
    J Bone Miner Res; 2009 Jan; 24(1):153-61. PubMed ID: 18767928
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate.
    Beck TJ; Lewiecki EM; Miller PD; Felsenberg D; Liu Y; Ding B; Libanati C
    J Clin Densitom; 2008; 11(3):351-9. PubMed ID: 18495508
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.
    Kendler DL; Roux C; Benhamou CL; Brown JP; Lillestol M; Siddhanti S; Man HS; San Martin J; Bone HG
    J Bone Miner Res; 2010 Jan; 25(1):72-81. PubMed ID: 19594293
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Denosumab: the era of targeted therapies in bone metastatic diseases.
    Santini D; Fratto ME; Vincenzi B; Napoli N; Galluzzo S; Tantardini M; Abbruzzese A; Caraglia M; Tonini G
    Curr Cancer Drug Targets; 2009 Nov; 9(7):834-42. PubMed ID: 20025571
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of RANKL-specific denosumab on osteoclast number and function: a potential friend or foe?
    Tankó LB
    Curr Opin Investig Drugs; 2007 Oct; 8(10):830-5. PubMed ID: 17907059
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The clinical use of denosumab for the management of low bone mineral density in postmenopausal women.
    Harris KB; Nealy KL; Jackson DJ; Thornton PL
    J Pharm Pract; 2012 Jun; 25(3):310-8. PubMed ID: 22550161
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bone health and prostate cancer.
    Saylor PJ; Smith MR
    Prostate Cancer Prostatic Dis; 2010 Mar; 13(1):20-7. PubMed ID: 19901958
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Denosumab - a new option in the treatment of osteoporosis].
    Franek E
    Endokrynol Pol; 2011; 62 Suppl 2():37-41. PubMed ID: 22125021
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Denosumab, the rheumatologist's joker?].
    Bérengère AR
    Rev Med Suisse; 2009 Jan; 5(185):59-62. PubMed ID: 19216327
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis.
    Josse R; Khan A; Ngui D; Shapiro M
    Curr Med Res Opin; 2013 Mar; 29(3):205-16. PubMed ID: 23297819
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [RANKL inhibition as therapy for joint damage].
    Akama H
    Nihon Rinsho Meneki Gakkai Kaishi; 2007 Oct; 30(5):404-7. PubMed ID: 17984581
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [ RANKL antibody for treatment of cancer treatment-induced bone loss (CTIBL)].
    Takahashi S
    Clin Calcium; 2011 Aug; 21(8):1239-47. PubMed ID: 21814031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.